iBio named endocrinologist Molly Carr as chief medical officer to lead global clinical strategy, medical affairs, regulatory work for its cardiometabolic pipeline.
Carr most recently served as clinical head, associate vice president of Eli Lilly’s Insulin and Glucagon Franchise, overseeing the Phase 3 efsitora program.
Her prior roles included senior positions at GlaxoSmithKline, CSL Behring, Wyeth, Northwestern University, the University of Washington.
IBIO•
